nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—CYP2A6—Prednisolone—multiple sclerosis	0.0888	0.134	CbGbCtD
Dapagliflozin—CYP2D6—Fingolimod—multiple sclerosis	0.0675	0.102	CbGbCtD
Dapagliflozin—CYP2A6—Dexamethasone—multiple sclerosis	0.0523	0.0791	CbGbCtD
Dapagliflozin—ABCB1—Methylprednisolone—multiple sclerosis	0.0462	0.0698	CbGbCtD
Dapagliflozin—CYP1A1—Dexamethasone—multiple sclerosis	0.0447	0.0676	CbGbCtD
Dapagliflozin—CYP3A4—Fingolimod—multiple sclerosis	0.0429	0.0649	CbGbCtD
Dapagliflozin—ABCB1—Mitoxantrone—multiple sclerosis	0.0337	0.0509	CbGbCtD
Dapagliflozin—ABCB1—Betamethasone—multiple sclerosis	0.03	0.0454	CbGbCtD
Dapagliflozin—ABCB1—Prednisolone—multiple sclerosis	0.0296	0.0448	CbGbCtD
Dapagliflozin—ABCB1—Prednisone—multiple sclerosis	0.028	0.0423	CbGbCtD
Dapagliflozin—CYP3A4—Methylprednisolone—multiple sclerosis	0.0277	0.0418	CbGbCtD
Dapagliflozin—CYP3A4—Triamcinolone—multiple sclerosis	0.021	0.0317	CbGbCtD
Dapagliflozin—CYP3A4—Mitoxantrone—multiple sclerosis	0.0202	0.0305	CbGbCtD
Dapagliflozin—CYP2C9—Dexamethasone—multiple sclerosis	0.018	0.0272	CbGbCtD
Dapagliflozin—CYP3A4—Betamethasone—multiple sclerosis	0.018	0.0272	CbGbCtD
Dapagliflozin—CYP3A4—Prednisolone—multiple sclerosis	0.0177	0.0268	CbGbCtD
Dapagliflozin—ABCB1—Dexamethasone—multiple sclerosis	0.0175	0.0264	CbGbCtD
Dapagliflozin—CYP3A4—Prednisone—multiple sclerosis	0.0168	0.0253	CbGbCtD
Dapagliflozin—CYP2D6—Dexamethasone—multiple sclerosis	0.0165	0.0249	CbGbCtD
Dapagliflozin—ABCB1—Methotrexate—multiple sclerosis	0.014	0.0212	CbGbCtD
Dapagliflozin—CYP3A4—Dexamethasone—multiple sclerosis	0.0105	0.0158	CbGbCtD
Dapagliflozin—SLC5A11—medulla oblongata—multiple sclerosis	0.00502	0.108	CbGeAlD
Dapagliflozin—SLC5A11—midbrain—multiple sclerosis	0.00458	0.0985	CbGeAlD
Dapagliflozin—SLC5A11—spinal cord—multiple sclerosis	0.00447	0.0961	CbGeAlD
Dapagliflozin—SLC5A4—nervous system—multiple sclerosis	0.00415	0.0892	CbGeAlD
Dapagliflozin—SLC5A4—central nervous system—multiple sclerosis	0.004	0.0859	CbGeAlD
Dapagliflozin—SLC5A11—nervous system—multiple sclerosis	0.00377	0.081	CbGeAlD
Dapagliflozin—SLC5A11—central nervous system—multiple sclerosis	0.00363	0.078	CbGeAlD
Dapagliflozin—SLC5A11—cerebellum—multiple sclerosis	0.00355	0.0762	CbGeAlD
Dapagliflozin—Canagliflozin—ALB—multiple sclerosis	0.00324	1	CrCbGaD
Dapagliflozin—SLC5A4—brain—multiple sclerosis	0.00317	0.0682	CbGeAlD
Dapagliflozin—SLC5A11—brain—multiple sclerosis	0.00288	0.0619	CbGeAlD
Dapagliflozin—Fracture—Methylprednisolone—multiple sclerosis	0.00162	0.00976	CcSEcCtD
Dapagliflozin—Fungal infection—Mitoxantrone—multiple sclerosis	0.00162	0.00976	CcSEcCtD
Dapagliflozin—Phlebitis—Cladribine—multiple sclerosis	0.0016	0.00966	CcSEcCtD
Dapagliflozin—Multiple fractures—Betamethasone—multiple sclerosis	0.00147	0.00888	CcSEcCtD
Dapagliflozin—Multiple fractures—Dexamethasone—multiple sclerosis	0.00147	0.00888	CcSEcCtD
Dapagliflozin—Fracture—Betamethasone—multiple sclerosis	0.00147	0.00888	CcSEcCtD
Dapagliflozin—Fracture—Dexamethasone—multiple sclerosis	0.00147	0.00888	CcSEcCtD
Dapagliflozin—Extravasation—Mitoxantrone—multiple sclerosis	0.00143	0.00864	CcSEcCtD
Dapagliflozin—Back pain—Fingolimod—multiple sclerosis	0.00142	0.00855	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Cladribine—multiple sclerosis	0.00141	0.00849	CcSEcCtD
Dapagliflozin—Neoplasm—Azathioprine—multiple sclerosis	0.0014	0.00843	CcSEcCtD
Dapagliflozin—Pain in extremity—Cladribine—multiple sclerosis	0.00138	0.00832	CcSEcCtD
Dapagliflozin—Fracture—Prednisone—multiple sclerosis	0.00128	0.00773	CcSEcCtD
Dapagliflozin—Multiple fractures—Prednisone—multiple sclerosis	0.00128	0.00773	CcSEcCtD
Dapagliflozin—Hypertension—Fingolimod—multiple sclerosis	0.00127	0.00763	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.00124	0.00748	CcSEcCtD
Dapagliflozin—Fungal infection—Methylprednisolone—multiple sclerosis	0.00122	0.00735	CcSEcCtD
Dapagliflozin—Infection—Fingolimod—multiple sclerosis	0.00119	0.00717	CcSEcCtD
Dapagliflozin—Blood urea increased—Mitoxantrone—multiple sclerosis	0.00118	0.00712	CcSEcCtD
Dapagliflozin—Skin disorder—Fingolimod—multiple sclerosis	0.00116	0.00701	CcSEcCtD
Dapagliflozin—Hypotension—Fingolimod—multiple sclerosis	0.00112	0.00674	CcSEcCtD
Dapagliflozin—Fungal infection—Betamethasone—multiple sclerosis	0.00111	0.00668	CcSEcCtD
Dapagliflozin—Fungal infection—Dexamethasone—multiple sclerosis	0.00111	0.00668	CcSEcCtD
Dapagliflozin—Multiple fractures—Methotrexate—multiple sclerosis	0.00107	0.00646	CcSEcCtD
Dapagliflozin—Fracture—Methotrexate—multiple sclerosis	0.00107	0.00646	CcSEcCtD
Dapagliflozin—Infestation—Cladribine—multiple sclerosis	0.00106	0.00641	CcSEcCtD
Dapagliflozin—Infestation NOS—Cladribine—multiple sclerosis	0.00106	0.00641	CcSEcCtD
Dapagliflozin—Phlebitis—Mitoxantrone—multiple sclerosis	0.00105	0.00635	CcSEcCtD
Dapagliflozin—Renal failure—Cladribine—multiple sclerosis	0.00105	0.0063	CcSEcCtD
Dapagliflozin—Urinary tract infection—Cladribine—multiple sclerosis	0.00104	0.00623	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00103	0.00623	CcSEcCtD
Dapagliflozin—Extravasation—Betamethasone—multiple sclerosis	0.000982	0.00591	CcSEcCtD
Dapagliflozin—Extravasation—Dexamethasone—multiple sclerosis	0.000982	0.00591	CcSEcCtD
Dapagliflozin—Fungal infection—Prednisone—multiple sclerosis	0.000966	0.00582	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Cladribine—multiple sclerosis	0.000944	0.00569	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Cladribine—multiple sclerosis	0.000939	0.00566	CcSEcCtD
Dapagliflozin—Urethral disorder—Cladribine—multiple sclerosis	0.000937	0.00564	CcSEcCtD
Dapagliflozin—Hyponatraemia—Mitoxantrone—multiple sclerosis	0.000912	0.00549	CcSEcCtD
Dapagliflozin—Lung disorder—Methotrexate—multiple sclerosis	0.000881	0.00531	CcSEcCtD
Dapagliflozin—Infestation NOS—Azathioprine—multiple sclerosis	0.000866	0.00522	CcSEcCtD
Dapagliflozin—Infestation—Azathioprine—multiple sclerosis	0.000866	0.00522	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Prednisolone—multiple sclerosis	0.000857	0.00516	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Mitoxantrone—multiple sclerosis	0.000851	0.00513	CcSEcCtD
Dapagliflozin—Dehydration—Mitoxantrone—multiple sclerosis	0.000845	0.00509	CcSEcCtD
Dapagliflozin—Malnutrition—Cladribine—multiple sclerosis	0.000832	0.00501	CcSEcCtD
Dapagliflozin—CYP2A6—cerebellum—multiple sclerosis	0.000816	0.0175	CbGeAlD
Dapagliflozin—Fungal infection—Methotrexate—multiple sclerosis	0.000807	0.00486	CcSEcCtD
Dapagliflozin—Back pain—Cladribine—multiple sclerosis	0.000805	0.00485	CcSEcCtD
Dapagliflozin—Dizziness—Fingolimod—multiple sclerosis	0.000792	0.00477	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Triamcinolone—multiple sclerosis	0.000788	0.00475	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Methylprednisolone—multiple sclerosis	0.000786	0.00473	CcSEcCtD
Dapagliflozin—Headache—Fingolimod—multiple sclerosis	0.000751	0.00452	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Dexamethasone—multiple sclerosis	0.000715	0.00431	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Betamethasone—multiple sclerosis	0.000715	0.00431	CcSEcCtD
Dapagliflozin—Extravasation—Methotrexate—multiple sclerosis	0.000715	0.0043	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.000704	0.00424	CcSEcCtD
Dapagliflozin—Discomfort—Cladribine—multiple sclerosis	0.0007	0.00422	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Mitoxantrone—multiple sclerosis	0.00069	0.00416	CcSEcCtD
Dapagliflozin—Renal failure—Mitoxantrone—multiple sclerosis	0.000688	0.00414	CcSEcCtD
Dapagliflozin—Myocardial infarction—Mitoxantrone—multiple sclerosis	0.000686	0.00413	CcSEcCtD
Dapagliflozin—Urinary tract infection—Mitoxantrone—multiple sclerosis	0.00068	0.0041	CcSEcCtD
Dapagliflozin—Oedema—Cladribine—multiple sclerosis	0.000679	0.00409	CcSEcCtD
Dapagliflozin—Infection—Cladribine—multiple sclerosis	0.000675	0.00406	CcSEcCtD
Dapagliflozin—CYP2A6—brain—multiple sclerosis	0.000663	0.0142	CbGeAlD
Dapagliflozin—Skin disorder—Cladribine—multiple sclerosis	0.00066	0.00397	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Cladribine—multiple sclerosis	0.000657	0.00395	CcSEcCtD
Dapagliflozin—Hypotension—Cladribine—multiple sclerosis	0.000635	0.00382	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Prednisone—multiple sclerosis	0.000623	0.00375	CcSEcCtD
Dapagliflozin—CYP2D6—brainstem—multiple sclerosis	0.000619	0.0133	CbGeAlD
Dapagliflozin—Influenza—Triamcinolone—multiple sclerosis	0.000592	0.00357	CcSEcCtD
Dapagliflozin—Vaginal infection—Methotrexate—multiple sclerosis	0.000589	0.00355	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000586	0.00353	CcSEcCtD
Dapagliflozin—Constipation—Cladribine—multiple sclerosis	0.000581	0.0035	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000572	0.00345	CcSEcCtD
Dapagliflozin—Discomfort—Azathioprine—multiple sclerosis	0.000569	0.00343	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Prednisolone—multiple sclerosis	0.000566	0.00341	CcSEcCtD
Dapagliflozin—Urine output increased—Methotrexate—multiple sclerosis	0.000564	0.00339	CcSEcCtD
Dapagliflozin—Neoplasm—Methotrexate—multiple sclerosis	0.000564	0.00339	CcSEcCtD
Dapagliflozin—Myocardial infarction—Prednisolone—multiple sclerosis	0.000563	0.00339	CcSEcCtD
Dapagliflozin—Infection—Azathioprine—multiple sclerosis	0.000549	0.0033	CcSEcCtD
Dapagliflozin—Urticaria—Cladribine—multiple sclerosis	0.00054	0.00325	CcSEcCtD
Dapagliflozin—Body temperature increased—Cladribine—multiple sclerosis	0.000537	0.00323	CcSEcCtD
Dapagliflozin—Skin disorder—Azathioprine—multiple sclerosis	0.000536	0.00323	CcSEcCtD
Dapagliflozin—Back pain—Mitoxantrone—multiple sclerosis	0.000529	0.00319	CcSEcCtD
Dapagliflozin—Infestation—Methylprednisolone—multiple sclerosis	0.000527	0.00317	CcSEcCtD
Dapagliflozin—Infestation NOS—Methylprednisolone—multiple sclerosis	0.000527	0.00317	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Triamcinolone—multiple sclerosis	0.000521	0.00314	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Methotrexate—multiple sclerosis	0.00052	0.00313	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Methylprednisolone—multiple sclerosis	0.000519	0.00313	CcSEcCtD
Dapagliflozin—Myocardial infarction—Triamcinolone—multiple sclerosis	0.000518	0.00312	CcSEcCtD
Dapagliflozin—Myocardial infarction—Methylprednisolone—multiple sclerosis	0.000516	0.00311	CcSEcCtD
Dapagliflozin—Hypotension—Azathioprine—multiple sclerosis	0.000516	0.00311	CcSEcCtD
Dapagliflozin—Polyuria—Methotrexate—multiple sclerosis	0.000515	0.0031	CcSEcCtD
Dapagliflozin—Hypersensitivity—Cladribine—multiple sclerosis	0.0005	0.00301	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000477	0.00287	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Betamethasone—multiple sclerosis	0.000472	0.00285	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Dexamethasone—multiple sclerosis	0.000472	0.00285	CcSEcCtD
Dapagliflozin—Hypertension—Mitoxantrone—multiple sclerosis	0.000472	0.00284	CcSEcCtD
Dapagliflozin—Myocardial infarction—Dexamethasone—multiple sclerosis	0.00047	0.00283	CcSEcCtD
Dapagliflozin—Myocardial infarction—Betamethasone—multiple sclerosis	0.00047	0.00283	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000465	0.0028	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Methotrexate—multiple sclerosis	0.000462	0.00278	CcSEcCtD
Dapagliflozin—Discomfort—Mitoxantrone—multiple sclerosis	0.00046	0.00277	CcSEcCtD
Dapagliflozin—CYP1A1—nervous system—multiple sclerosis	0.000449	0.00965	CbGeAlD
Dapagliflozin—Dizziness—Cladribine—multiple sclerosis	0.000449	0.00271	CcSEcCtD
Dapagliflozin—Oedema—Mitoxantrone—multiple sclerosis	0.000446	0.00269	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000446	0.00269	CcSEcCtD
Dapagliflozin—Infection—Mitoxantrone—multiple sclerosis	0.000443	0.00267	CcSEcCtD
Dapagliflozin—Body temperature increased—Azathioprine—multiple sclerosis	0.000437	0.00263	CcSEcCtD
Dapagliflozin—Skin disorder—Mitoxantrone—multiple sclerosis	0.000434	0.00261	CcSEcCtD
Dapagliflozin—CYP1A1—central nervous system—multiple sclerosis	0.000432	0.00929	CbGeAlD
Dapagliflozin—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.000432	0.0026	CcSEcCtD
Dapagliflozin—ABCB1—retina—multiple sclerosis	0.00043	0.00923	CbGeAlD
Dapagliflozin—Rash—Cladribine—multiple sclerosis	0.000428	0.00258	CcSEcCtD
Dapagliflozin—Dermatitis—Cladribine—multiple sclerosis	0.000428	0.00258	CcSEcCtD
Dapagliflozin—Headache—Cladribine—multiple sclerosis	0.000425	0.00256	CcSEcCtD
Dapagliflozin—Hypotension—Mitoxantrone—multiple sclerosis	0.000417	0.00251	CcSEcCtD
Dapagliflozin—Malnutrition—Methylprednisolone—multiple sclerosis	0.000412	0.00248	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Prednisone—multiple sclerosis	0.000411	0.00248	CcSEcCtD
Dapagliflozin—Angioedema—Prednisolone—multiple sclerosis	0.00041	0.00247	CcSEcCtD
Dapagliflozin—Myocardial infarction—Prednisone—multiple sclerosis	0.000409	0.00246	CcSEcCtD
Dapagliflozin—Hypersensitivity—Azathioprine—multiple sclerosis	0.000407	0.00245	CcSEcCtD
Dapagliflozin—Nausea—Cladribine—multiple sclerosis	0.000403	0.00243	CcSEcCtD
Dapagliflozin—Back pain—Triamcinolone—multiple sclerosis	0.000399	0.0024	CcSEcCtD
Dapagliflozin—Hypertension—Prednisolone—multiple sclerosis	0.000387	0.00233	CcSEcCtD
Dapagliflozin—Constipation—Mitoxantrone—multiple sclerosis	0.000382	0.0023	CcSEcCtD
Dapagliflozin—Discomfort—Prednisolone—multiple sclerosis	0.000377	0.00227	CcSEcCtD
Dapagliflozin—Angioedema—Triamcinolone—multiple sclerosis	0.000377	0.00227	CcSEcCtD
Dapagliflozin—Angioedema—Methylprednisolone—multiple sclerosis	0.000376	0.00227	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Prednisone—multiple sclerosis	0.000368	0.00222	CcSEcCtD
Dapagliflozin—Oedema—Prednisolone—multiple sclerosis	0.000366	0.00221	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000366	0.00221	CcSEcCtD
Dapagliflozin—Dysuria—Methotrexate—multiple sclerosis	0.000366	0.0022	CcSEcCtD
Dapagliflozin—Dizziness—Azathioprine—multiple sclerosis	0.000365	0.0022	CcSEcCtD
Dapagliflozin—Hypertension—Triamcinolone—multiple sclerosis	0.000356	0.00215	CcSEcCtD
Dapagliflozin—Hypertension—Methylprednisolone—multiple sclerosis	0.000355	0.00214	CcSEcCtD
Dapagliflozin—Urticaria—Mitoxantrone—multiple sclerosis	0.000355	0.00214	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000354	0.00213	CcSEcCtD
Dapagliflozin—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000353	0.00213	CcSEcCtD
Dapagliflozin—Infestation NOS—Methotrexate—multiple sclerosis	0.000349	0.0021	CcSEcCtD
Dapagliflozin—Infestation—Methotrexate—multiple sclerosis	0.000349	0.0021	CcSEcCtD
Dapagliflozin—Rash—Azathioprine—multiple sclerosis	0.000348	0.0021	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000348	0.0021	CcSEcCtD
Dapagliflozin—Dermatitis—Azathioprine—multiple sclerosis	0.000348	0.0021	CcSEcCtD
Dapagliflozin—Discomfort—Triamcinolone—multiple sclerosis	0.000347	0.00209	CcSEcCtD
Dapagliflozin—Discomfort—Methylprednisolone—multiple sclerosis	0.000346	0.00209	CcSEcCtD
Dapagliflozin—Headache—Azathioprine—multiple sclerosis	0.000346	0.00208	CcSEcCtD
Dapagliflozin—CYP1A1—brain—multiple sclerosis	0.000343	0.00738	CbGeAlD
Dapagliflozin—Renal failure—Methotrexate—multiple sclerosis	0.000343	0.00206	CcSEcCtD
Dapagliflozin—Angioedema—Betamethasone—multiple sclerosis	0.000342	0.00206	CcSEcCtD
Dapagliflozin—Angioedema—Dexamethasone—multiple sclerosis	0.000342	0.00206	CcSEcCtD
Dapagliflozin—Oedema—Triamcinolone—multiple sclerosis	0.000337	0.00203	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000337	0.00203	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000336	0.00202	CcSEcCtD
Dapagliflozin—Infection—Triamcinolone—multiple sclerosis	0.000335	0.00202	CcSEcCtD
Dapagliflozin—Infection—Methylprednisolone—multiple sclerosis	0.000334	0.00201	CcSEcCtD
Dapagliflozin—CYP3A4—nervous system—multiple sclerosis	0.00033	0.00708	CbGeAlD
Dapagliflozin—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000329	0.00198	CcSEcCtD
Dapagliflozin—Nausea—Azathioprine—multiple sclerosis	0.000328	0.00198	CcSEcCtD
Dapagliflozin—Skin disorder—Methylprednisolone—multiple sclerosis	0.000326	0.00197	CcSEcCtD
Dapagliflozin—Malnutrition—Prednisone—multiple sclerosis	0.000326	0.00196	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000326	0.00196	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000325	0.00196	CcSEcCtD
Dapagliflozin—CYP2D6—nervous system—multiple sclerosis	0.000324	0.00697	CbGeAlD
Dapagliflozin—Hypertension—Dexamethasone—multiple sclerosis	0.000323	0.00195	CcSEcCtD
Dapagliflozin—Hypertension—Betamethasone—multiple sclerosis	0.000323	0.00195	CcSEcCtD
Dapagliflozin—CYP3A4—central nervous system—multiple sclerosis	0.000317	0.00682	CbGeAlD
Dapagliflozin—Discomfort—Dexamethasone—multiple sclerosis	0.000315	0.0019	CcSEcCtD
Dapagliflozin—Discomfort—Betamethasone—multiple sclerosis	0.000315	0.0019	CcSEcCtD
Dapagliflozin—Hypotension—Methylprednisolone—multiple sclerosis	0.000314	0.00189	CcSEcCtD
Dapagliflozin—CYP2D6—central nervous system—multiple sclerosis	0.000312	0.00671	CbGeAlD
Dapagliflozin—ABCB1—medulla oblongata—multiple sclerosis	0.00031	0.00667	CbGeAlD
Dapagliflozin—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000309	0.00186	CcSEcCtD
Dapagliflozin—Urethral disorder—Methotrexate—multiple sclerosis	0.000307	0.00185	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000306	0.00184	CcSEcCtD
Dapagliflozin—Oedema—Dexamethasone—multiple sclerosis	0.000306	0.00184	CcSEcCtD
Dapagliflozin—Oedema—Betamethasone—multiple sclerosis	0.000306	0.00184	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000306	0.00184	CcSEcCtD
Dapagliflozin—CYP2D6—cerebellum—multiple sclerosis	0.000305	0.00656	CbGeAlD
Dapagliflozin—Infection—Betamethasone—multiple sclerosis	0.000304	0.00183	CcSEcCtD
Dapagliflozin—Infection—Dexamethasone—multiple sclerosis	0.000304	0.00183	CcSEcCtD
Dapagliflozin—Angioedema—Prednisone—multiple sclerosis	0.000298	0.00179	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000295	0.00178	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000295	0.00178	CcSEcCtD
Dapagliflozin—Urticaria—Prednisolone—multiple sclerosis	0.000291	0.00175	CcSEcCtD
Dapagliflozin—Hypotension—Dexamethasone—multiple sclerosis	0.000286	0.00172	CcSEcCtD
Dapagliflozin—Hypotension—Betamethasone—multiple sclerosis	0.000286	0.00172	CcSEcCtD
Dapagliflozin—ABCB1—midbrain—multiple sclerosis	0.000284	0.0061	CbGeAlD
Dapagliflozin—Hypertension—Prednisone—multiple sclerosis	0.000282	0.0017	CcSEcCtD
Dapagliflozin—Rash—Mitoxantrone—multiple sclerosis	0.000281	0.0017	CcSEcCtD
Dapagliflozin—Dermatitis—Mitoxantrone—multiple sclerosis	0.000281	0.00169	CcSEcCtD
Dapagliflozin—Headache—Mitoxantrone—multiple sclerosis	0.00028	0.00168	CcSEcCtD
Dapagliflozin—ABCB1—spinal cord—multiple sclerosis	0.000277	0.00595	CbGeAlD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000276	0.00166	CcSEcCtD
Dapagliflozin—Discomfort—Prednisone—multiple sclerosis	0.000274	0.00165	CcSEcCtD
Dapagliflozin—Malnutrition—Methotrexate—multiple sclerosis	0.000273	0.00164	CcSEcCtD
Dapagliflozin—Hypersensitivity—Prednisolone—multiple sclerosis	0.00027	0.00163	CcSEcCtD
Dapagliflozin—Urticaria—Triamcinolone—multiple sclerosis	0.000268	0.00161	CcSEcCtD
Dapagliflozin—Urticaria—Methylprednisolone—multiple sclerosis	0.000267	0.00161	CcSEcCtD
Dapagliflozin—Body temperature increased—Triamcinolone—multiple sclerosis	0.000266	0.0016	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Prednisone—multiple sclerosis	0.000266	0.0016	CcSEcCtD
Dapagliflozin—Oedema—Prednisone—multiple sclerosis	0.000266	0.0016	CcSEcCtD
Dapagliflozin—Nausea—Mitoxantrone—multiple sclerosis	0.000265	0.0016	CcSEcCtD
Dapagliflozin—Infection—Prednisone—multiple sclerosis	0.000264	0.00159	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000264	0.00159	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000264	0.00159	CcSEcCtD
Dapagliflozin—Back pain—Methotrexate—multiple sclerosis	0.000264	0.00159	CcSEcCtD
Dapagliflozin—Skin disorder—Prednisone—multiple sclerosis	0.000259	0.00156	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Prednisone—multiple sclerosis	0.000257	0.00155	CcSEcCtD
Dapagliflozin—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000248	0.00149	CcSEcCtD
Dapagliflozin—CYP2D6—brain—multiple sclerosis	0.000248	0.00533	CbGeAlD
Dapagliflozin—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000248	0.00149	CcSEcCtD
Dapagliflozin—Urticaria—Dexamethasone—multiple sclerosis	0.000243	0.00146	CcSEcCtD
Dapagliflozin—Urticaria—Betamethasone—multiple sclerosis	0.000243	0.00146	CcSEcCtD
Dapagliflozin—Dizziness—Prednisolone—multiple sclerosis	0.000242	0.00146	CcSEcCtD
Dapagliflozin—Body temperature increased—Betamethasone—multiple sclerosis	0.000242	0.00146	CcSEcCtD
Dapagliflozin—Body temperature increased—Dexamethasone—multiple sclerosis	0.000242	0.00146	CcSEcCtD
Dapagliflozin—ABCB1—nervous system—multiple sclerosis	0.000233	0.00501	CbGeAlD
Dapagliflozin—Rash—Prednisolone—multiple sclerosis	0.000231	0.00139	CcSEcCtD
Dapagliflozin—Dermatitis—Prednisolone—multiple sclerosis	0.000231	0.00139	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00023	0.00139	CcSEcCtD
Dapagliflozin—Headache—Prednisolone—multiple sclerosis	0.000229	0.00138	CcSEcCtD
Dapagliflozin—Discomfort—Methotrexate—multiple sclerosis	0.000229	0.00138	CcSEcCtD
Dapagliflozin—Constipation—Prednisone—multiple sclerosis	0.000228	0.00137	CcSEcCtD
Dapagliflozin—ABCB1—central nervous system—multiple sclerosis	0.000225	0.00483	CbGeAlD
Dapagliflozin—Dizziness—Triamcinolone—multiple sclerosis	0.000223	0.00134	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000222	0.00134	CcSEcCtD
Dapagliflozin—Dizziness—Methylprednisolone—multiple sclerosis	0.000222	0.00134	CcSEcCtD
Dapagliflozin—Infection—Methotrexate—multiple sclerosis	0.000221	0.00133	CcSEcCtD
Dapagliflozin—ABCB1—cerebellum—multiple sclerosis	0.00022	0.00472	CbGeAlD
Dapagliflozin—Nausea—Prednisolone—multiple sclerosis	0.000218	0.00131	CcSEcCtD
Dapagliflozin—Skin disorder—Methotrexate—multiple sclerosis	0.000216	0.0013	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000215	0.0013	CcSEcCtD
Dapagliflozin—Rash—Triamcinolone—multiple sclerosis	0.000212	0.00128	CcSEcCtD
Dapagliflozin—Dermatitis—Triamcinolone—multiple sclerosis	0.000212	0.00128	CcSEcCtD
Dapagliflozin—Rash—Methylprednisolone—multiple sclerosis	0.000212	0.00128	CcSEcCtD
Dapagliflozin—Dermatitis—Methylprednisolone—multiple sclerosis	0.000212	0.00128	CcSEcCtD
Dapagliflozin—Urticaria—Prednisone—multiple sclerosis	0.000211	0.00127	CcSEcCtD
Dapagliflozin—Headache—Triamcinolone—multiple sclerosis	0.000211	0.00127	CcSEcCtD
Dapagliflozin—Headache—Methylprednisolone—multiple sclerosis	0.000211	0.00127	CcSEcCtD
Dapagliflozin—Body temperature increased—Prednisone—multiple sclerosis	0.00021	0.00127	CcSEcCtD
Dapagliflozin—Hypotension—Methotrexate—multiple sclerosis	0.000208	0.00125	CcSEcCtD
Dapagliflozin—Dizziness—Betamethasone—multiple sclerosis	0.000202	0.00122	CcSEcCtD
Dapagliflozin—Dizziness—Dexamethasone—multiple sclerosis	0.000202	0.00122	CcSEcCtD
Dapagliflozin—Nausea—Triamcinolone—multiple sclerosis	0.0002	0.0012	CcSEcCtD
Dapagliflozin—Nausea—Methylprednisolone—multiple sclerosis	0.0002	0.0012	CcSEcCtD
Dapagliflozin—Hypersensitivity—Prednisone—multiple sclerosis	0.000196	0.00118	CcSEcCtD
Dapagliflozin—Rash—Dexamethasone—multiple sclerosis	0.000193	0.00116	CcSEcCtD
Dapagliflozin—Rash—Betamethasone—multiple sclerosis	0.000193	0.00116	CcSEcCtD
Dapagliflozin—Dermatitis—Dexamethasone—multiple sclerosis	0.000193	0.00116	CcSEcCtD
Dapagliflozin—Dermatitis—Betamethasone—multiple sclerosis	0.000193	0.00116	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000192	0.00116	CcSEcCtD
Dapagliflozin—Headache—Betamethasone—multiple sclerosis	0.000191	0.00115	CcSEcCtD
Dapagliflozin—Headache—Dexamethasone—multiple sclerosis	0.000191	0.00115	CcSEcCtD
Dapagliflozin—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	0.000189	0.00154	CbGpPWpGaD
Dapagliflozin—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000188	0.00153	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.000184	0.0015	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000182	0.00148	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000182	0.00148	CbGpPWpGaD
Dapagliflozin—Nausea—Dexamethasone—multiple sclerosis	0.000182	0.00109	CcSEcCtD
Dapagliflozin—Nausea—Betamethasone—multiple sclerosis	0.000182	0.00109	CcSEcCtD
Dapagliflozin—ABCB1—brain—multiple sclerosis	0.000178	0.00383	CbGeAlD
Dapagliflozin—Urticaria—Methotrexate—multiple sclerosis	0.000177	0.00106	CcSEcCtD
Dapagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000176	0.00144	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000176	0.00143	CbGpPWpGaD
Dapagliflozin—Dizziness—Prednisone—multiple sclerosis	0.000176	0.00106	CcSEcCtD
Dapagliflozin—Body temperature increased—Methotrexate—multiple sclerosis	0.000176	0.00106	CcSEcCtD
Dapagliflozin—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.000175	0.00142	CbGpPWpGaD
Dapagliflozin—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	0.000173	0.00141	CbGpPWpGaD
Dapagliflozin—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	0.000173	0.00141	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000171	0.00139	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000171	0.00139	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.000168	0.00137	CbGpPWpGaD
Dapagliflozin—Rash—Prednisone—multiple sclerosis	0.000168	0.00101	CcSEcCtD
Dapagliflozin—Dermatitis—Prednisone—multiple sclerosis	0.000168	0.00101	CcSEcCtD
Dapagliflozin—Headache—Prednisone—multiple sclerosis	0.000167	0.001	CcSEcCtD
Dapagliflozin—UGT2B4—Metabolism—RRM1—multiple sclerosis	0.000166	0.00135	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	0.000165	0.00135	CbGpPWpGaD
Dapagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000165	0.00134	CbGpPWpGaD
Dapagliflozin—Hypersensitivity—Methotrexate—multiple sclerosis	0.000164	0.000987	CcSEcCtD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—ALB—multiple sclerosis	0.000164	0.00133	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—BCHE—multiple sclerosis	0.000163	0.00132	CbGpPWpGaD
Dapagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.00016	0.0013	CbGpPWpGaD
Dapagliflozin—Nausea—Prednisone—multiple sclerosis	0.000158	0.000952	CcSEcCtD
Dapagliflozin—CYP2A6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000154	0.00126	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—CD28—multiple sclerosis	0.000154	0.00125	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CD28—multiple sclerosis	0.000154	0.00125	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000151	0.00123	CbGpPWpGaD
Dapagliflozin—Dizziness—Methotrexate—multiple sclerosis	0.000147	0.000886	CcSEcCtD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000146	0.00119	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	0.000146	0.00119	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—CD86—multiple sclerosis	0.000145	0.00118	CbGpPWpGaD
Dapagliflozin—CYP1A1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000142	0.00116	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—SRM—multiple sclerosis	0.000141	0.00115	CbGpPWpGaD
Dapagliflozin—Rash—Methotrexate—multiple sclerosis	0.00014	0.000845	CcSEcCtD
Dapagliflozin—Dermatitis—Methotrexate—multiple sclerosis	0.00014	0.000844	CcSEcCtD
Dapagliflozin—Headache—Methotrexate—multiple sclerosis	0.000139	0.000839	CcSEcCtD
Dapagliflozin—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	0.000136	0.00111	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000134	0.00109	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000134	0.00109	CbGpPWpGaD
Dapagliflozin—Nausea—Methotrexate—multiple sclerosis	0.000132	0.000796	CcSEcCtD
Dapagliflozin—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000132	0.00107	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000132	0.00107	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—CD86—multiple sclerosis	0.000131	0.00107	CbGpPWpGaD
Dapagliflozin—UGT2B7—Biological oxidations—POMC—multiple sclerosis	0.000131	0.00107	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.00013	0.00106	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.00013	0.00106	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	0.000129	0.00105	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL10—multiple sclerosis	0.000129	0.00105	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—CCR5—multiple sclerosis	0.000128	0.00105	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL4—multiple sclerosis	0.000125	0.00102	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—HLA-A—multiple sclerosis	0.000125	0.00102	CbGpPWpGaD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—ALB—multiple sclerosis	0.000124	0.00101	CbGpPWpGaD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	0.000124	0.00101	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—BCHE—multiple sclerosis	0.000123	0.001	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—BCHE—multiple sclerosis	0.000123	0.001	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	0.000122	0.000997	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—APOE—multiple sclerosis	0.000117	0.000951	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—FAS—multiple sclerosis	0.000115	0.00094	CbGpPWpGaD
Dapagliflozin—CYP1A1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000115	0.000937	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—SRM—multiple sclerosis	0.000115	0.000935	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	0.000115	0.000934	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	0.000113	0.000924	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CD86—multiple sclerosis	0.00011	0.000894	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—CD86—multiple sclerosis	0.00011	0.000894	CbGpPWpGaD
Dapagliflozin—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000107	0.00087	CbGpPWpGaD
Dapagliflozin—UGT1A9—Biological oxidations—POMC—multiple sclerosis	0.000106	0.000867	CbGpPWpGaD
Dapagliflozin—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000106	0.000863	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—CD80—multiple sclerosis	0.000106	0.00086	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000104	0.00085	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000104	0.00085	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	0.000104	0.000844	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	0.000101	0.000826	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000101	0.000824	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CYP27B1—multiple sclerosis	9.95e-05	0.000811	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CYP24A1—multiple sclerosis	9.95e-05	0.000811	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	9.93e-05	0.000809	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—APOE—multiple sclerosis	9.78e-05	0.000797	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CCR5—multiple sclerosis	9.73e-05	0.000792	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—CCR5—multiple sclerosis	9.73e-05	0.000792	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—CD80—multiple sclerosis	9.57e-05	0.00078	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—BCHE—multiple sclerosis	9.51e-05	0.000775	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—HLA-A—multiple sclerosis	9.48e-05	0.000772	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—HLA-A—multiple sclerosis	9.48e-05	0.000772	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	9.45e-05	0.00077	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	9.45e-05	0.00077	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	9.31e-05	0.000758	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GPC5—multiple sclerosis	9.1e-05	0.000742	CbGpPWpGaD
Dapagliflozin—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.05e-05	0.000737	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—TYK2—multiple sclerosis	8.91e-05	0.000726	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—APOE—multiple sclerosis	8.85e-05	0.000721	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—APOE—multiple sclerosis	8.85e-05	0.000721	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—SRM—multiple sclerosis	8.85e-05	0.000721	CbGpPWpGaD
Dapagliflozin—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.66e-05	0.000705	CbGpPWpGaD
Dapagliflozin—UGT2B7—NRF2 pathway—TGFB1—multiple sclerosis	8.61e-05	0.000701	CbGpPWpGaD
Dapagliflozin—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.58e-05	0.000699	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	8.52e-05	0.000694	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—POMC—multiple sclerosis	8.4e-05	0.000684	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	8.3e-05	0.000677	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	8.29e-05	0.000675	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	8.27e-05	0.000674	CbGpPWpGaD
Dapagliflozin—CYP2A6—Biological oxidations—POMC—multiple sclerosis	8.2e-05	0.000668	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP27B1—multiple sclerosis	8.09e-05	0.000659	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP24A1—multiple sclerosis	8.09e-05	0.000659	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—CD4—multiple sclerosis	8.06e-05	0.000657	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—CD80—multiple sclerosis	8e-05	0.000652	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CD80—multiple sclerosis	8e-05	0.000652	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	7.91e-05	0.000644	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	7.78e-05	0.000634	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	7.78e-05	0.000634	CbGpPWpGaD
Dapagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	7.7e-05	0.000628	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—ALB—multiple sclerosis	7.66e-05	0.000624	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	7.57e-05	0.000616	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—RRM1—multiple sclerosis	7.54e-05	0.000615	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—APOE—multiple sclerosis	7.41e-05	0.000604	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—APOE—multiple sclerosis	7.41e-05	0.000604	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GPC5—multiple sclerosis	7.4e-05	0.000603	CbGpPWpGaD
Dapagliflozin—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.34e-05	0.000598	CbGpPWpGaD
Dapagliflozin—UGT1A9—NRF2 pathway—TGFB1—multiple sclerosis	6.99e-05	0.00057	CbGpPWpGaD
Dapagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.98e-05	0.000569	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—TYK2—multiple sclerosis	6.76e-05	0.00055	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—TYK2—multiple sclerosis	6.76e-05	0.00055	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	6.75e-05	0.00055	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL2—multiple sclerosis	6.72e-05	0.000548	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	6.65e-05	0.000542	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.65e-05	0.000542	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.65e-05	0.000542	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—SRM—multiple sclerosis	6.59e-05	0.000537	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	6.47e-05	0.000527	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	6.46e-05	0.000526	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	6.45e-05	0.000526	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—POMC—multiple sclerosis	6.37e-05	0.000519	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—POMC—multiple sclerosis	6.37e-05	0.000519	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	6.33e-05	0.000516	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—STAT3—multiple sclerosis	6.24e-05	0.000508	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP27B1—multiple sclerosis	6.24e-05	0.000508	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP24A1—multiple sclerosis	6.24e-05	0.000508	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—RRM1—multiple sclerosis	6.13e-05	0.000499	CbGpPWpGaD
Dapagliflozin—CYP1A1—Biological oxidations—POMC—multiple sclerosis	6.11e-05	0.000498	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CD4—multiple sclerosis	6.11e-05	0.000498	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—CD4—multiple sclerosis	6.11e-05	0.000498	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	6.03e-05	0.000491	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	6.03e-05	0.000491	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—ALB—multiple sclerosis	5.81e-05	0.000473	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—ALB—multiple sclerosis	5.81e-05	0.000473	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—MYC—multiple sclerosis	5.8e-05	0.000472	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—TGFB1—multiple sclerosis	5.79e-05	0.000471	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—APOE—multiple sclerosis	5.72e-05	0.000466	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GPC5—multiple sclerosis	5.7e-05	0.000465	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	5.69e-05	0.000464	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—MAPK1—multiple sclerosis	5.67e-05	0.000462	CbGpPWpGaD
Dapagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.66e-05	0.000461	CbGpPWpGaD
Dapagliflozin—CYP2A6—NRF2 pathway—TGFB1—multiple sclerosis	5.39e-05	0.000439	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SRM—multiple sclerosis	5.27e-05	0.000429	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	5.24e-05	0.000427	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	5.11e-05	0.000416	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SRM—multiple sclerosis	4.96e-05	0.000404	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SRM—multiple sclerosis	4.92e-05	0.000401	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—POMC—multiple sclerosis	4.92e-05	0.0004	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—TNF—multiple sclerosis	4.9e-05	0.000399	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	4.76e-05	0.000387	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—STAT3—multiple sclerosis	4.73e-05	0.000385	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—STAT3—multiple sclerosis	4.73e-05	0.000385	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—RRM1—multiple sclerosis	4.73e-05	0.000385	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP27B1—multiple sclerosis	4.65e-05	0.000378	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP24A1—multiple sclerosis	4.65e-05	0.000378	CbGpPWpGaD
Dapagliflozin—CYP2D6—Biological oxidations—POMC—multiple sclerosis	4.6e-05	0.000375	CbGpPWpGaD
Dapagliflozin—CYP2C9—Biological oxidations—POMC—multiple sclerosis	4.56e-05	0.000371	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.54e-05	0.00037	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	4.51e-05	0.000368	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—ALB—multiple sclerosis	4.48e-05	0.000365	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—MYC—multiple sclerosis	4.4e-05	0.000358	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—MYC—multiple sclerosis	4.4e-05	0.000358	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—TGFB1—multiple sclerosis	4.38e-05	0.000357	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—TGFB1—multiple sclerosis	4.38e-05	0.000357	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—IL6—multiple sclerosis	4.36e-05	0.000355	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—BCHE—multiple sclerosis	4.33e-05	0.000353	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—MAPK1—multiple sclerosis	4.3e-05	0.00035	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—MAPK1—multiple sclerosis	4.3e-05	0.00035	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GPC5—multiple sclerosis	4.25e-05	0.000346	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SRM—multiple sclerosis	4.2e-05	0.000342	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.09e-05	0.000333	CbGpPWpGaD
Dapagliflozin—CYP1A2—Biological oxidations—POMC—multiple sclerosis	3.9e-05	0.000317	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.72e-05	0.000303	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP27B1—multiple sclerosis	3.71e-05	0.000302	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP24A1—multiple sclerosis	3.71e-05	0.000302	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—RRM1—multiple sclerosis	3.52e-05	0.000287	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—BCHE—multiple sclerosis	3.52e-05	0.000287	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	3.5e-05	0.000285	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	3.5e-05	0.000285	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	3.47e-05	0.000282	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	3.47e-05	0.000282	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GPC5—multiple sclerosis	3.39e-05	0.000276	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.39e-05	0.000276	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—IL6—multiple sclerosis	3.3e-05	0.000269	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—IL6—multiple sclerosis	3.3e-05	0.000269	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SRM—multiple sclerosis	3.24e-05	0.000264	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GPC5—multiple sclerosis	3.2e-05	0.000261	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GPC5—multiple sclerosis	3.17e-05	0.000258	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—POMC—multiple sclerosis	3.01e-05	0.000245	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	2.96e-05	0.000241	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	2.96e-05	0.000241	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.9e-05	0.000236	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—RRM1—multiple sclerosis	2.81e-05	0.000229	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.73e-05	0.000223	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—BCHE—multiple sclerosis	2.71e-05	0.000221	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GPC5—multiple sclerosis	2.71e-05	0.000221	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—RRM1—multiple sclerosis	2.65e-05	0.000216	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—RRM1—multiple sclerosis	2.63e-05	0.000214	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—APOE—multiple sclerosis	2.61e-05	0.000212	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.59e-05	0.000211	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.59e-05	0.000211	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.54e-05	0.000207	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.42e-05	0.000197	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.35e-05	0.000191	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	2.29e-05	0.000186	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	2.29e-05	0.000186	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—RRM1—multiple sclerosis	2.24e-05	0.000183	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—POMC—multiple sclerosis	2.24e-05	0.000182	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.14e-05	0.000174	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—APOE—multiple sclerosis	2.12e-05	0.000173	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GPC5—multiple sclerosis	2.09e-05	0.00017	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ALB—multiple sclerosis	2.04e-05	0.000166	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.04e-05	0.000166	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—BCHE—multiple sclerosis	2.02e-05	0.000165	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—POMC—multiple sclerosis	1.82e-05	0.000148	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.75e-05	0.000143	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.74e-05	0.000142	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.73e-05	0.000141	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ALB—multiple sclerosis	1.66e-05	0.000135	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—APOE—multiple sclerosis	1.63e-05	0.000133	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.62e-05	0.000132	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—BCHE—multiple sclerosis	1.62e-05	0.000132	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.6e-05	0.00013	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—BCHE—multiple sclerosis	1.52e-05	0.000124	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—BCHE—multiple sclerosis	1.51e-05	0.000123	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.5e-05	0.000122	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—POMC—multiple sclerosis	1.4e-05	0.000114	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.36e-05	0.000111	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—BCHE—multiple sclerosis	1.29e-05	0.000105	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ALB—multiple sclerosis	1.28e-05	0.000104	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—APOE—multiple sclerosis	1.22e-05	9.91e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—POMC—multiple sclerosis	1.05e-05	8.51e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—BCHE—multiple sclerosis	9.95e-06	8.11e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—APOE—multiple sclerosis	9.72e-06	7.91e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ALB—multiple sclerosis	9.53e-06	7.76e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—APOE—multiple sclerosis	9.16e-06	7.46e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APOE—multiple sclerosis	9.08e-06	7.39e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—POMC—multiple sclerosis	8.35e-06	6.8e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—POMC—multiple sclerosis	7.87e-06	6.41e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—POMC—multiple sclerosis	7.8e-06	6.35e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APOE—multiple sclerosis	7.76e-06	6.32e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ALB—multiple sclerosis	7.61e-06	6.2e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ALB—multiple sclerosis	7.17e-06	5.84e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ALB—multiple sclerosis	7.11e-06	5.79e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—POMC—multiple sclerosis	6.66e-06	5.43e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ALB—multiple sclerosis	6.07e-06	4.95e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOE—multiple sclerosis	5.99e-06	4.88e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—POMC—multiple sclerosis	5.14e-06	4.19e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ALB—multiple sclerosis	4.69e-06	3.82e-05	CbGpPWpGaD
